Key points are not available for this paper at this time.
This article presents the results of a comprehensive survey on the adoption of electrochemistry among 17 major pharmaceutical companies. The study examined key areas, including motivation, vision, personnel, utilization, explored reactions, scale-up experience, and equipment, with a focus on identifying gaps that hinder the realization of electrochemistry’s full potential. The survey findings suggest that although the adoption of electrochemistry is still in its early stages, it is viewed as a promising area that could lead to novel, better, and differentiated chemical transformations and disruptive routes. None of the surveyed companies reported having commercialized electrochemical processes; however, many anticipate reaching late-stage development or commercialization within a few years. The survey provides valuable insights for both industrial and academic laboratories seeking to pursue research in this field. Addressing gaps in knowledge and technology is essential to realizing the potential benefits of electrochemistry, ultimately contributing to the development of more efficient and sustainable manufacturing processes in the pharmaceutical industry.
Ferretti et al. (Mon,) studied this question.